TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Feasibility study to assess a novel combination of cytotoxic agents, docetaxel and
oxaliplatin, as first-line therapy in the treatment of ovarian cancer and the impact of
angiogenesis inhibition for the progression and prognosis of ovarian cancer by concurrent
addition of bevacizumab (Avastin®).